NYSE:RCUS Arcus Biosciences (RCUS) Stock Forecast, Price & News $20.58 +0.41 (+2.03%) (As of 06/7/2023 ET) Add Compare Share Share Today's Range$19.80▼$20.7950-Day Range$16.97▼$22.0352-Week Range$15.70▼$36.13Volume996,201 shsAverage Volume1.05 million shsMarket Capitalization$1.50 billionP/E RatioN/ADividend YieldN/APrice Target$41.44 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial Media Arcus Biosciences MarketRank™ ForecastAnalyst RatingModerate Buy2.89 Rating ScoreUpside/Downside101.4% Upside$41.44 Price TargetShort InterestBearish18.25% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.30Based on 10 Articles This WeekInsider TradingSelling Shares$146,734 Sold Last QuarterProj. Earnings GrowthGrowingFrom ($4.31) to ($3.30) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.03 out of 5 starsMedical Sector475th out of 982 stocksPharmaceutical Preparations Industry218th out of 470 stocks 3.4 Analyst's Opinion Consensus RatingArcus Biosciences has received a consensus rating of Buy. The company's average rating score is 2.89, and is based on 8 buy ratings, 1 hold rating, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $41.44, Arcus Biosciences has a forecasted upside of 101.4% from its current price of $20.58.Amount of Analyst CoverageArcus Biosciences has only been the subject of 1 research reports in the past 90 days. Previous Next 1.0 Short Interest Percentage of Shares Shorted18.25% of the float of Arcus Biosciences has been sold short.Short Interest Ratio / Days to CoverArcus Biosciences has a short interest ratio ("days to cover") of 9.Change versus previous monthShort interest in Arcus Biosciences has recently increased by 11.14%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldArcus Biosciences does not currently pay a dividend.Dividend GrowthArcus Biosciences does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for RCUS. Previous Next 2.4 News and Social Media Coverage News SentimentArcus Biosciences has a news sentiment score of 0.30. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.51 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 10 news articles for Arcus Biosciences this week, compared to 3 articles on an average week.Search Interest4 people have searched for RCUS on MarketBeat in the last 30 days. This is an increase of 300% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added Arcus Biosciences to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Arcus Biosciences insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $146,734.00 in company stock.Percentage Held by Insiders13.80% of the stock of Arcus Biosciences is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions72.97% of the stock of Arcus Biosciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Arcus Biosciences are expected to grow in the coming year, from ($4.31) to ($3.30) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Arcus Biosciences is -5.35, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Arcus Biosciences is -5.35, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioArcus Biosciences has a P/B Ratio of 2.27. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Arcus Biosciences (NYSE:RCUS) StockArcus Biosciences, Inc. engages in the development and commercialization of immunotherapies. It competes in the segments of the pharmaceutical, biotechnology and other related markets that develop immunotherapies for the treatment of cancer. The company was founded by Terry J. Rosen and Juan Carlos Jaen in 2015 and is headquartered in Hayward, CA.Read More Receive RCUS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Arcus Biosciences and its competitors with MarketBeat's FREE daily newsletter. Email Address RCUS Stock News HeadlinesJune 6, 2023 | americanbankingnews.comArcus Biosciences, Inc. (NYSE:RCUS) Receives Average Rating of "Moderate Buy" from AnalystsJune 5, 2023 | finance.yahoo.comGilead (GILD), Arcus Announce Results From Mid-Stage NSCLC StudyJune 7, 2023 | Behind the Markets (Ad)Small A.I. Firm Wins $2 Billion in Contracts for Breakthrough "Living Software"Denver firm proves its possible to use AI to save the lives of soldiers in combat. England, Germany, Japan and Australia have all signed contracts within the past 18 months. Get the name of the stock here >>>June 5, 2023 | markets.businessinsider.comBank of America Securities Sticks to Its Hold Rating for Arcus Biosciences (RCUS)June 3, 2023 | finance.yahoo.comGilead and Arcus Announce Anti-TIGIT Domvanalimab Continues to Demonstrate Consistent Improvement in Progression-Free Survival in Non-Small Cell Lung Cancer StudyJune 2, 2023 | msn.comHC Wainwright & Co. Reiterates Precision Biosciences (DTIL) Buy RecommendationJune 1, 2023 | markets.businessinsider.comArcus Biosciences (RCUS) Receives a Hold from Bank of America SecuritiesMay 30, 2023 | finance.yahoo.comArcus Biosciences to Participate in the Goldman Sachs 44th Annual Global Healthcare ConferenceJune 7, 2023 | Behind the Markets (Ad)Small A.I. Firm Wins $2 Billion in Contracts for Breakthrough "Living Software"Denver firm proves its possible to use AI to save the lives of soldiers in combat. England, Germany, Japan and Australia have all signed contracts within the past 18 months. Get the name of the stock here >>>May 28, 2023 | americanbankingnews.comArcus Biosciences (NYSE:RCUS) Shares Gap Up on Analyst UpgradeMay 27, 2023 | msn.comCitigroup Maintains Arcus Biosciences (RCUS) Buy RecommendationMay 27, 2023 | msn.comUnusual Call Option Trade in Arcus Biosciences (RCUS) Worth $164.80KMay 26, 2023 | msn.comBooz Allen Hamilton, Workday, Marvell Technology And Other Big Stocks Moving Higher On FridayMay 26, 2023 | markets.businessinsider.comCitigroup Maintains Buy Rating for Arcus Biosciences: Here's What You Need To KnowMay 26, 2023 | finance.yahoo.comArcus, Iteos Soar On Roche's 'Meaningful' Results In A New Cancer Drug ClassMay 26, 2023 | finance.yahoo.comArcus Biosciences Soars On Roche's 'Meaningful' Results In A New Cancer Drug ClassMay 26, 2023 | americanbankingnews.comArcus Biosciences (NYSE:RCUS) Price Target Raised to $41.00 at CitigroupMay 26, 2023 | markets.businessinsider.comMizuho Securities Reaffirms Their Buy Rating on Arcus Biosciences (RCUS)May 24, 2023 | finance.yahoo.comPrecision BioSciences to Participate in Upcoming Stifel Genetic Medicines DayMay 20, 2023 | americanbankingnews.comQ2 2023 Earnings Estimate for Arcus Biosciences, Inc. Issued By Wedbush (NYSE:RCUS)May 17, 2023 | finance.yahoo.comPresentations at the 2023 ASCO Annual Meeting Highlight Arcus Biosciences’ Expanding Portfolio of Investigational Medicines and Late-Stage Studies Across Multiple Types of CancerMay 17, 2023 | americanbankingnews.comArcus Biosciences (NYSE:RCUS) Trading 6.5% Higher May 17, 2023 | americanbankingnews.comEquities Analysts Set Expectations for Arcus Biosciences, Inc.'s FY2023 Earnings (NYSE:RCUS)May 16, 2023 | finance.yahoo.comThe past three years for Arcus Biosciences (NYSE:RCUS) investors has not been profitableMay 15, 2023 | finance.yahoo.comGilead Sciences and Arcus Biosciences Expand Partnership to Include Research Programs in InflammationMay 14, 2023 | americanbankingnews.comArcus Biosciences, Inc. Expected to Earn Q2 2023 Earnings of ($1.23) Per Share (NYSE:RCUS)May 12, 2023 | msn.comWedbush Reiterates Arcus Biosciences (RCUS) Outperform RecommendationSee More Headlines RCUS Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart RCUS Company Calendar Last Earnings5/09/2023Today6/07/2023Next Earnings (Estimated)8/02/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSE Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNYSE:RCUS CUSIPN/A CIK1724521 Webwww.arcusbio.com Phone(510) 694-6200FaxN/AEmployees366Year FoundedN/APrice Target and Rating Average Stock Price Forecast$41.44 High Stock Price Forecast$51.00 Low Stock Price Forecast$33.00 Forecasted Upside/Downside+99.7%Consensus RatingModerate Buy Rating Score (0-4)2.89 Research Coverage9 Analysts Profitability EPS (Most Recent Fiscal Year)($3.85) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-267,000,000.00 Net Margins-233.41% Pretax Margin-232.11% Return on Equity-41.22% Return on Assets-20.37% Debt Debt-to-Equity RatioN/A Current Ratio5.67 Quick Ratio5.67 Sales & Book Value Annual Sales$112 million Price / Sales13.54 Cash FlowN/A Price / Cash FlowN/A Book Value$9.07 per share Price / Book2.29Miscellaneous Outstanding Shares73,110,000Free Float63,017,000Market Cap$1.52 billion OptionableOptionable Beta0.87 Key ExecutivesTerry J. RosenChairman & Chief Executive OfficerJuan Carlos JaenPresident & DirectorJennifer A. JarrettChief Operating Officer & DirectorRobert C. GoeltzChief Financial OfficerSteve YoungSenior VP-Technology & Quantitative BiologyKey CompetitorsMoonLake ImmunotherapeuticsNASDAQ:MLTXTaro Pharmaceutical IndustriesNYSE:TARO89bioNASDAQ:ETNBDynavax TechnologiesNASDAQ:DVAXAgios PharmaceuticalsNASDAQ:AGIOView All CompetitorsInsiders & InstitutionsCapital Impact Advisors LLCBought 4,344 shares on 5/23/2023Ownership: 0.028%Ameriprise Financial Inc.Sold 9,067 shares on 5/22/2023Ownership: 0.267%JPMorgan Chase & Co.Bought 25,084 shares on 5/18/2023Ownership: 0.739%New York State Common Retirement FundSold 2,818 shares on 5/18/2023Ownership: 0.068%Thrivent Financial for LutheransSold 1,811 shares on 5/17/2023Ownership: 0.071%View All Insider TransactionsView All Institutional Transactions RCUS Stock - Frequently Asked Questions Should I buy or sell Arcus Biosciences stock right now? 9 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Arcus Biosciences in the last year. There are currently 1 hold rating and 8 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" RCUS shares. View RCUS analyst ratings or view top-rated stocks. What is Arcus Biosciences' stock price forecast for 2023? 9 Wall Street analysts have issued 12-month price targets for Arcus Biosciences' stock. Their RCUS share price forecasts range from $33.00 to $51.00. On average, they expect the company's share price to reach $41.44 in the next twelve months. This suggests a possible upside of 99.7% from the stock's current price. View analysts price targets for RCUS or view top-rated stocks among Wall Street analysts. How have RCUS shares performed in 2023? Arcus Biosciences' stock was trading at $20.68 on January 1st, 2023. Since then, RCUS stock has increased by 0.3% and is now trading at $20.75. View the best growth stocks for 2023 here. When is Arcus Biosciences' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, August 2nd 2023. View our RCUS earnings forecast. How were Arcus Biosciences' earnings last quarter? Arcus Biosciences, Inc. (NYSE:RCUS) posted its quarterly earnings results on Tuesday, May, 9th. The company reported ($1.09) EPS for the quarter, missing the consensus estimate of ($1.06) by $0.03. The firm had revenue of $25 million for the quarter, compared to analyst estimates of $22.47 million. Arcus Biosciences had a negative net margin of 233.41% and a negative trailing twelve-month return on equity of 41.22%. The firm's quarterly revenue was up 38.9% compared to the same quarter last year. During the same quarter last year, the company earned ($0.96) earnings per share. What ETFs hold Arcus Biosciences' stock? ETFs with the largest weight of Arcus Biosciences (NYSE:RCUS) stock in their portfolio include Loncar Cancer Immunotherapy ETF (CNCR), iShares Genomics Immunology and Healthcare ETF (IDNA), SPDR S&P Biotech ETF (XBI), Invesco S&P SmallCap Health Care ETF (PSCH), ALPS Medical Breakthroughs ETF (SBIO), First Trust Innovation Leaders ETF (ILDR), Direxion Daily S&P Biotech Bull 3x Shares (LABU) and Virtus LifeSci Biotech Clinical Trials ETF (BBC). What is Terry Rosen, Ph.D.'s approval rating as Arcus Biosciences' CEO? 4 employees have rated Arcus Biosciences Chief Executive Officer Terry Rosen, Ph.D. on Glassdoor.com. Terry Rosen, Ph.D. has an approval rating of 100% among the company's employees. This puts Terry Rosen, Ph.D. in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. What other stocks do shareholders of Arcus Biosciences own? Based on aggregate information from My MarketBeat watchlists, some companies that other Arcus Biosciences investors own include Horizon Therapeutics Public (HZNP), BioDelivery Sciences International (BDSI), Pfizer (PFE), Sorrento Therapeutics (SRNE), VBI Vaccines (VBIV), CRISPR Therapeutics (CRSP), Gilead Sciences (GILD), Inovio Pharmaceuticals (INO), Agile Therapeutics (AGRX) and Advanced Micro Devices (AMD). When did Arcus Biosciences IPO? (RCUS) raised $99 million in an initial public offering on Thursday, March 15th 2018. The company issued 7,100,000 shares at a price of $13.00-$15.00 per share. Citigroup, Goldman Sachs and Leerink Partners acted as the underwriters for the IPO. What is Arcus Biosciences' stock symbol? Arcus Biosciences trades on the New York Stock Exchange (NYSE) under the ticker symbol "RCUS." Who are Arcus Biosciences' major shareholders? Arcus Biosciences' stock is owned by a number of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (13.87%), State Street Corp (7.52%), FMR LLC (4.53%), Dimensional Fund Advisors LP (1.79%), Pictet Asset Management SA (1.76%) and Bank of America Corp DE (1.57%). Insiders that own company stock include Carolyn C Tang, Carolyn C Tang, Gilead Sciences Inc, Jennifer Jarrett, Juan C Jaen, Kathryn E Falberg, Robert C Goeltz II, Terry J Rosen, William Grossman and Yasunori Kaneko. View institutional ownership trends. How do I buy shares of Arcus Biosciences? Shares of RCUS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Arcus Biosciences' stock price today? One share of RCUS stock can currently be purchased for approximately $20.75. How much money does Arcus Biosciences make? Arcus Biosciences (NYSE:RCUS) has a market capitalization of $1.52 billion and generates $112 million in revenue each year. The company earns $-267,000,000.00 in net income (profit) each year or ($3.85) on an earnings per share basis. How many employees does Arcus Biosciences have? The company employs 366 workers across the globe. How can I contact Arcus Biosciences? Arcus Biosciences' mailing address is 3928 Point Eden Way, Hayward CA, 94545. The official website for the company is www.arcusbio.com. The company can be reached via phone at (510) 694-6200 or via email at investorinfo@arcusbio.com. This page (NYSE:RCUS) was last updated on 6/7/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Arcus Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.